Alpha Tau Medical stock holds Buy rating at H.C. Wainwright after license win

Investing.com - H.C. Wainwright has reiterated its Buy rating and $9.00 price target on Alpha Tau Medical Ltd. (NASDAQ:DRTS), whose shares have surged over 40% in the past six months, following the company’s receipt of a radioactive material license in New Hampshire. The stock currently trades at $4.04, with analyst targets ranging from $5 to $12.

Alpha Tau Medical announced on October 21 that it secured the license from the New Hampshire Bureau of Public Health Protection, Radiological Health Section, after completing the first phase of construction at its commercial-scale manufacturing facility in Hudson, NH.

The facility, being built in multiple phases, has an expected nameplate capacity of approximately 400,000 Alpha DaRT sources for local use from its first construction phase. With the license now secured, the company can proceed with equipping the facility, verification and validation, and introducing thorium generators.

Alpha Tau Medical aims to produce Alpha DaRT treatments at the Hudson facility during 2026, establishing U.S.-based manufacturing capabilities for both clinical trials and future commercialization efforts.

H.C. Wainwright views this development as an operational milestone for the company, supporting its maintained Buy rating and $9 price target on Alpha Tau Medical stock.

In other recent news, Alpha Tau Medical announced that the first patient has been treated in its U.S. pilot study of Alpha DaRT for pancreatic cancer. This study, known as IMPACT (Intratumoral Pancreatic Alpha Combination Trial, NCT06698458), marks a significant step in the company’s research efforts. Following this development, H.C. Wainwright reiterated its Buy rating on Alpha Tau Medical, maintaining a price target of $9. These updates reflect the company’s ongoing commitment to advancing its medical research and have been noted by analysts. The reiteration of the Buy rating suggests continued confidence from H.C. Wainwright in Alpha Tau Medical’s potential. These recent developments are part of the company’s broader strategy to explore innovative treatments in the medical field.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.